SAR348830 | CAS# 1462949-64-9 | inhibitor of anaplastic lymphoma kinase

MedKoo Cat#: 581028 | Name: SAR348830

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SAR348830 is novel potent and selective inhibitor of anaplastic lymphoma kinase (ALK).

Chemical Structure

SAR348830

CAS#1462949-64-9

Theoretical Analysis

MedKoo Cat#: 581028

Name: SAR348830

CAS#: 1462949-64-9

Chemical Formula: C28H32FN5O3S

Exact Mass: 537.2210

Molecular Weight: 537.65

Elemental Analysis: C, 62.55; H, 6.00; F, 3.53; N, 13.03; O, 8.93; S, 5.96

Price and Availability

Size	Price	Availability
10mg	USD 150.00	2 Weeks
25mg	USD 250.00	2 Weeks
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,750.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

SAR348830; SAR 348830; SAR-348830; DC10499; HY-19990

IUPAC/Chemical Name

7-(5-Fluoro-2-methoxyphenyl)-2-[[2-(1-methylethoxy)-4-(4-methyl-1-piperazinyl)phenyl]amino]-thieno[3,2-d]pyrimidine-6-methanol

InChi Key

SWRGFJBGNAEJOY-UHFFFAOYSA-N

InChi Code

InChI=1S/C28H32FN5O3S/c1-17(2)37-23-14-19(34-11-9-33(3)10-12-34)6-7-21(23)31-28-30-15-24-27(32-28)26(25(16-35)38-24)20-13-18(29)5-8-22(20)36-4/h5-8,13-15,17,35H,9-12,16H2,1-4H3,(H,30,31,32)

SMILES Code

OCC1=C(C2=CC(F)=CC=C2OC)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4OC(C)C)=NC=C3S1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

SAR348830 is an ALK inhibitor.

In vitro activity:

To be determined

In vivo activity:

To be determined

	Solvent	mg/mL	mM
Solubility
	DMSO	100.0	185.99

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 537.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

To be determined

In vitro protocol:

To be determined

In vivo protocol:

To be determined

1: Oya Y, Yoshida T, Kuroda H, Shimizu J, Horio Y, Sakao Y, Hida T, Yatabe Y. Clinical Efficacy of Alectinib in Patients with ALK-Rearranged Non-small Cell Lung Cancer After Ceritinib Failure. Anticancer Res. 2017 Nov;37(11):6477-6480. PubMed PMID: 29061835. 2: Geller S, Canavan TN, Pulitzer M, Moskowitz AJ, Myskowski PL. ALK-positive primary cutaneous anaplastic large cell lymphoma: a case report and review of the literature. Int J Dermatol. 2017 Oct 23. doi: 10.1111/ijd.13804. [Epub ahead of print] Review. PubMed PMID: 29057463. 3: West H. Prioritizing molecular markers to test for in the initial workup of advanced non-small cell lung cancer: wants versus needs. Ann Transl Med. 2017 Sep;5(18):371. doi: 10.21037/atm.2017.08.29. Review. PubMed PMID: 29057231; PubMed Central PMCID: PMC5635256. 4: Leberfinger AN, Behar BJ, Williams NC, Rakszawski KL, Potochny JD, Mackay DR, Ravnic DJ. Breast Implant-Associated Anaplastic Large Cell Lymphoma: A Systematic Review. JAMA Surg. 2017 Oct 18. doi: 10.1001/jamasurg.2017.4026. [Epub ahead of print] PubMed PMID: 29049466. 5: Yoshida R, Sasaki T, Minami Y, Hibino Y, Okumura S, Sado M, Miyokawa N, Hayashi S, Kitada M, Ohsaki Y. Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancer. Int J Oncol. 2017 Sep 28. doi: 10.3892/ijo.2017.4140. [Epub ahead of print] PubMed PMID: 29048652. 6: Zeng L, Kang R, Zhu S, Wang X, Cao L, Wang H, Billiar TR, Jiang J, Tang D. ALK is a therapeutic target for lethal sepsis. Sci Transl Med. 2017 Oct 18;9(412). pii: eaan5689. doi: 10.1126/scitranslmed.aan5689. PubMed PMID: 29046432. 7: Dolgikh N, Fulda S. Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status. Anticancer Drugs. 2017 Nov;28(10):1118-1125. doi: 10.1097/CAD.0000000000000552. PubMed PMID: 29045271. 8: Werner MT, Zhang Q, Wasik MA. From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL). Cancers (Basel). 2017 Oct 16;9(10). pii: E138. doi: 10.3390/cancers9100138. Review. PubMed PMID: 29035291. 9: Iijima-Yamashita Y, Mori T, Nakazawa A, Fukano R, Takimoto T, Tsurusawa M, Kobayashi R, Horibe K. Prognostic impact of minimal disseminated disease and immune response to NPM-ALK in Japanese children with ALK-positive anaplastic large cell lymphoma. Int J Hematol. 2017 Oct 13. doi: 10.1007/s12185-017-2338-6. [Epub ahead of print] PubMed PMID: 29030834. 10: Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A. Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionisation mass spectrometry imaging: A pilot study. Br J Pharmacol. 2017 Oct 13. doi: 10.1111/bph.14067. [Epub ahead of print] PubMed PMID: 29027209. 11: Oyama Y, Nishida H, Kusaba T, Kadowaki H, Arakane M, Daa T, Watanabe D, Akita Y, Sato F, Mimata H, Yokoyama S. A case of anaplastic lymphoma kinase-positive renal cell carcinoma coincident with Hodgkin lymphoma. Pathol Int. 2017 Oct 12. doi: 10.1111/pin.12592. [Epub ahead of print] PubMed PMID: 29024210. 12: Chaudhari N, Talwar P, Lefebvre D'hellencourt C, Ravanan P. CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells. Front Mol Neurosci. 2017 Sep 26;10:310. doi: 10.3389/fnmol.2017.00310. eCollection 2017. PubMed PMID: 29018329; PubMed Central PMCID: PMC5623017. 13: Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017 Oct 9. doi: 10.1038/nchembio.2489. [Epub ahead of print] PubMed PMID: 28991240. 14: Muller IB, de Langen AJ, Giovannetti E, Peters GJ. Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib. Onco Targets Ther. 2017 Sep 13;10:4535-4541. doi: 10.2147/OTT.S109493. eCollection 2017. Review. PubMed PMID: 28979145; PubMed Central PMCID: PMC5602476. 15: Saiki M, Ohyanagi F, Ariyasu R, Koyama J, Sonoda T, Nishikawa S, Kitazono S, Yanagitani N, Horiike A, Ninomiya H, Ishikawa Y, Nishio M. Dramatic response to alectinib in inflammatory myofibroblastic tumor with anaplastic lymphoma kinase fusion gene. Jpn J Clin Oncol. 2017 Sep 18:1-4. doi: 10.1093/jjco/hyx133. [Epub ahead of print] PubMed PMID: 28977547. 16: Kwatra KS, Paul PAM, Calton N, John JM, Cotelingam JD. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile. South Asian J Cancer. 2017 Jul-Sep;6(3):129-131. doi: 10.4103/2278-330X.214575. PubMed PMID: 28975123; PubMed Central PMCID: PMC5615884. 17: Vendrell JA, Taviaux S, Béganton B, Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V, Coopman P, Mazières J, Costes V, Pujol JL, Brousset P, Rouquette I, Solassol J. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8. PubMed PMID: 28970558; PubMed Central PMCID: PMC5624911. 18: Wu D, Liu L, Yan X, Wang C, Wang Y, Han K, Lin S, Gan Z, Min D. Pleiotrophin promotes chemoresistance to doxorubicin in osteosarcoma by upregulating P-glycoprotein. Oncotarget. 2017 Jul 10;8(38):63857-63870. doi: 10.18632/oncotarget.19148. eCollection 2017 Sep 8. PubMed PMID: 28969035; PubMed Central PMCID: PMC5609967. 19: Otsuki Y, Saya H, Arima Y. Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn. 2017 Sep 27. doi: 10.1002/dvdy.24596. [Epub ahead of print] Review. PubMed PMID: 28960588. 20: Takeuchi S, Murayama T, Yoshimura K, Kawakami T, Takahara S, Imai Y, Kuribayashi Y, Nagase K, Goto K, Nishio M, Hasegawa Y, Satouchi M, Kiura K, Seto T, Yano S. Phase I/II study of alectinib in lung cancer with RET fusion gene: study protocol. J Med Invest. 2017;64(3.4):317-320. doi: 10.2152/jmi.64.317. PubMed PMID: 28955006.